Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Early diagnosis in advanced pancreatic cancer: how will we achieve this?

Michel Ducreux • 1 Oct 2019
ESMO 2019
Pancreatic Cancer FOLFIRINOX Gemcitabine Nab-paclitaxel

Michel Ducreux, MD, PhD, Gustave Roussy Institute, Villejuif, France, emphasizes the importance of early diagnosis in a disease as fast-moving as pancreatic cancer. Dr Ducreux suggests doing this by educating the public as to the symptoms, in an attempt to speed up the staging process and begin treatment as soon as possible. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Michel Ducreux

The changing treatment landscape in hepatocellular carcinoma
0:46
The changing treatment landscape in hepatocellular carcinoma
Michel Ducreux • 2 Jul 2026
GLEAM: biomarker and pharmacokinetic analyses of zolbetuximab in PAC
0:52
GLEAM: biomarker and pharmacokinetic analyses of zolbetuximab in PAC
Michel Ducreux • 2 Jul 2026
RASolute 304: adjuvant daraxonrasib vs observation in resected PDAC
0:39
RASolute 304: adjuvant daraxonrasib vs observation in resected PDAC
Michel Ducreux • 2 Jul 2026
NEOPAN: chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic cancer
1:59
NEOPAN: chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic cancer
Michel Ducreux • 30 May 2025

Related Videos

Surgical resection in locally advanced pancreatic cancer
1:42
Surgical resection in locally advanced pancreatic cancer
Michele Milella • 6 Jul 2026
How does P-32 microparticle brachytherapy compare with other locoregional techniques in uLAPC?
3:43
How does P-32 microparticle brachytherapy compare with other locoregional techniques in uLAPC?
Michele Milella • 6 Jul 2026
TRIPP-FFX: targeted intratumoral P-32 microparticles with FOLFIRINOX in uLAPC
7:07
TRIPP-FFX: targeted intratumoral P-32 microparticles with FOLFIRINOX in uLAPC
Michele Milella • 6 Jul 2026
GLEAM: zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2-positive mPAC
1:48
GLEAM: zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2-positive mPAC
Wungki Park • 2 Jul 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals